Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JALSG-GML219 intensive chemotherapy study in newly diagnosed elderly acute myeloid leukemia
jRCTs041190088Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daunorubicin, cytarabine, mitoxantrone and aclarubicin in acute myeloid leukemia (AML), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 2-year event-free survival. Started Dec 2019; status: active, not recruiting.
02
Drugs
daunorubicincytarabinemitoxantroneaclarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs041190088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190088.